Omecamtiv Mecarbil in Chronic Heart Failure with Reduced Ejection Fraction: GALACTIC-HF Baseline Characteristics and Comparison with Contemporary Clinical Trials

Abstract

GALACTIC-HF enrolled a well-treated, high-risk population from both inpatient and outpatient settings, which will provide a definitive evaluation of the efficacy and safety of this novel therapy, as well as informing its potential future implementation.